Aptinyx to Participate in H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Aptinyx Inc. (Nasdaq: APTX) announced its management will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The presentation will be available on-demand starting at 7:00 AM ET on May 24, 2022. A webcast recording can be accessed on Aptinyx's website for 30 days post-event. The company specializes in developing therapies for nervous system disorders, with three product candidates in clinical development targeting fibromyalgia, PTSD, and cognitive impairment.

EVANSTON, Ill.--(BUSINESS WIRE)-- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022. The presentation will be available on-demand through the H.C. Wainwright conference portal, beginning at 7:00 AM ET on Tuesday, May 24, 2022.

A webcast recording of the presentation will be available to view on the “Events and Presentations” page in the “Investors & Media” section of Aptinyx’s website at https://ir.aptinyx.com and will be archived on Aptinyx’s website for 30 days following the event.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including fibromyalgia, post-traumatic stress disorder, and cognitive impairment. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com or follow Aptinyx on Twitter @Aptinyx.

Source: Aptinyx Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005502/en/

Investor and Media Contact:

Patrick Flavin

Aptinyx Inc.

ir@aptinyx.com or corporate@aptinyx.com

847-871-0377

Source: Aptinyx Inc.

FAQ

When will Aptinyx present at the H.C. Wainwright Global Investment Conference?

Aptinyx will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022.

At what time will the Aptinyx presentation be available on-demand?

The presentation will be available on-demand starting at 7:00 AM ET on May 24, 2022.

Where can I find the webcast recording of the Aptinyx presentation?

The webcast recording will be available on the 'Events and Presentations' page in the 'Investors & Media' section of Aptinyx's website.

What are the main focus areas for Aptinyx's product candidates?

Aptinyx's product candidates focus on treating fibromyalgia, post-traumatic stress disorder (PTSD), and cognitive impairment.

How can I access the Aptinyx presentation after the conference?

The presentation will be archived on Aptinyx's website for 30 days following the event.